Climb Bio (NASDAQ:CLYM – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports.
Climb Bio Price Performance
Climb Bio stock opened at $1.30 on Thursday. The business’s 50-day moving average price is $1.57. The firm has a market cap of $87.39 million, a price-to-earnings ratio of -0.61 and a beta of -0.19. Climb Bio has a fifty-two week low of $1.20 and a fifty-two week high of $11.55.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. Leerink Partnrs raised Climb Bio to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on Climb Bio in a report on Monday, December 2nd. They issued an “outperform” rating and a $10.00 price objective for the company.
Climb Bio Company Profile
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also
- Five stocks we like better than Climb Bio
- How to Read Stock Charts for Beginners
- 2 Stocks With Strong Fundamentals Gaining Technical Momentum
- Learn Technical Analysis Skills to Master the Stock Market
- Up 32% in 2025, Is Chinese E-Commerce Giant PDD Still a Buy?
- 5 Top Rated Dividend Stocks to Consider
- Maybe It’s Time to Buy Some GameStop Stock
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
